Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • California
  • San Jose


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Telepsychology in Spinal Cord Injury
    NCT03711760
    Conditions:   Spinal Cord Injuries;   Depression
    Intervention:   Behavioral: telepsychology
    Sponsors:   Santa Clara Valley Health & Hospital System;   University of California, San Francisco
    Recruiting
  • Electrical Stimulation for Continence After Spinal Cord Injury
    NCT02978638
    Conditions:   Spinal Cord Injury;   Neurogenic Bladder;   Incontinence
    Intervention:   Device: Finetech Vocare Bladder System
    Sponsors:   Palo Alto Veterans Institute for Research;   VA Palo Alto Health Care System;   Stanford University;   Case Western Reserve University;   Santa Clara Valley Medical Center
    Recruiting
  • Patient Activation in Dialysis
    NCT04066140
    Conditions:   Renal Dialysis;   Kidney Failure, Chronic
    Intervention:   Other: No intervention
    Sponsor:   Satellite Healthcare
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
    NCT03150693
    Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Work Ability in Young Adult Cancer Survivors
    NCT03148080
    Condition:   Cancer Survivor
    Interventions:   Procedure: Cognitive Assessment;   Other: Questionnaire Administration
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)
    NCT03657043
    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
    Intervention:   Drug: tisotumab vedotin
    Sponsors:   Seattle Genetics, Inc.;   Genmab
    Recruiting
  • A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
    NCT03979638
    Condition:   Chronic Refractory Cough
    Interventions:   Drug: BLU-5937;   Drug: Placebo
    Sponsor:   Bellus Health Inc
    Recruiting
  • The INSPIRE-ASP UTI Trial
    NCT03697096
    Condition:   Urinary Tract Infection (UTI)
    Interventions:   Other: Routine Care;   Other: INSPIRE CPOE Smart Prompt
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting
  • The INSPIRE-ASP PNA Trial
    NCT03697070
    Condition:   Pneumonia
    Interventions:   Other: INSPIRE CPOE Smart Prompt;   Other: Routine Care
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting
  • Riluzole in Spinal Cord Injury Study
    NCT01597518
    Condition:   Spinal Cord Injury
    Interventions:   Drug: Riluzole;   Drug: Placebo
    Sponsors:   AOSpine North America Research Network;   AOSpine International;   United States Department of Defense;   Rick Hansen Institute;   Christopher Reeve Paralysis Foundation
    Recruiting
  • Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
    NCT04056299
    Condition:   Hen Egg Allergy
    Interventions:   Biological: AR201 Powder;   Biological: Placebo powder
    Sponsor:   Aimmune Therapeutics, Inc.
    Recruiting
  • A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
    NCT03831191
    Condition:   Atopic Dermatitis
    Interventions:   Drug: LY3375880;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes
    NCT02469519
    Condition:   Premature Birth
    Interventions:   Drug: Betamethasone - ACTIVE;   Other: Normal Saline - PLACEBO
    Sponsor:   Mednax Center for Research, Education, Quality and Safety
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps
    NCT03781804
    Condition:   Chronic Sinusitis
    Intervention:   Drug: OPN-375
    Sponsor:   Optinose US Inc.
    Recruiting
  • Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
    NCT03737994
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
    NCT03737643
    Condition:   Advanced Ovarian Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Durvalumab;   Drug: Olaparib;   Drug: Placebo olaparib;   Drug: Durvalumab placebo;   Drug: Carboplatin+Paclitaxel
    Sponsors:   AstraZeneca;   European Network of Gynaecological Oncological Trial Groups (ENGOT);   GOG Foundation, Inc. (GOG Foundation);   Myriad Genetic Laboratories, Inc.
    Recruiting
  • Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
    NCT03701282
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • GB001 in Adult Subjects With Moderate to Severe Asthma
    NCT03683576
    Condition:   Asthma
    Interventions:   Drug: GB001;   Drug: Placebo Oral Tablet
    Sponsor:   GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
    Recruiting
  • A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC
    NCT03661320
    Conditions:   Bladder Cancer;   Muscle-Invasive Bladder Cancer;   BMS-986205
    Interventions:   Biological: Nivolumab;   Drug: BMS-986205;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: BMS-986205 Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
    NCT03639246
    Condition:   Ovarian Cancer
    Interventions:   Drug: AVB-S6-500;   Drug: Paclitaxel (Pac);   Drug: Pegylated liposomal doxorubicin (PLD);   Other: Placebo
    Sponsor:   Aravive, Inc.
    Recruiting
  • Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
    NCT03596450
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Semaglutide;   Drug: Standard of care
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
    NCT03457896
    Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: Trastuzumab;   Drug: Cetuximab;   Drug: Neratinib;   Diagnostic Test: Guardant360 Diagnostic Test
    Sponsors:   NSABP Foundation Inc;   Puma Biotechnology, Inc.
    Recruiting
  • A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150]
    NCT03434379
    Condition:   Carcinoma, Hepatocellular
    Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Sorafenib
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
    NCT03418961
    Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
    NCT03375320
    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
    NCT03367702
    Condition:   Stage II Prostate Adenocarcinoma
    Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
    NCT03337724
    Condition:   Breast Cancer
    Interventions:   Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Palbociclib in Real World Practice
    NCT03280303
    Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
    Intervention:   Other: non-interventional
    Sponsor:   Pfizer
    Recruiting
  • Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
    NCT03258554
    Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group;   NRG Oncology
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
    NCT03219333
    Conditions:   Carcinoma, Transitional Cell;   Urinary Bladder Neoplasms;   Urologic Neoplasms;   Renal Pelvis Neoplasms;   Urothelial Cancer;   Ureteral Neoplasms;   Urethral Neoplasms
    Intervention:   Drug: Enfortumab vedotin
    Sponsors:   Astellas Pharma Global Development, Inc.;   Seattle Genetics, Inc.
    Recruiting
  • Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
    NCT03199885
    Conditions:   Breast Adenocarcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Biological: Pertuzumab;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
    NCT03180294
    Conditions:   Breast Carcinoma;   Cervical Carcinoma;   Ovarian Carcinoma;   Postmenopausal;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
    Interventions:   Drug: Bupropion Hydrochloride;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
    NCT03070886
    Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
    Interventions:   Drug: Bicalutamide;   Drug: Docetaxel;   Radiation: External Beam Radiation Therapy;   Drug: Flutamide;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Leuprolide Acetate;   Drug: Nilutamide
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
    NCT03055013
    Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
    Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    NCT02834013
    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
    NCT02822573
    Conditions:   Cognitive Dysfunction;   Memory Impairment
    Interventions:   Drug: Donepezil 5 mg;   Drug: Placebo
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
    NCT02466971
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT01896999
    Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
    NCT01805076
    Conditions:   Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
    Recruiting
  • Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
    NCT03204916
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • CLUSTER Trial for Outbreak Detection and Response
    NCT04053075
    Condition:   Cluster Detection
    Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
    Recruiting
  • Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
    NCT04099251
    Condition:   Melanoma
    Interventions:   Biological: Nivolumab;   Other: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
    NCT03580356
    Condition:   Chronic Spontaneous Urticaria
    Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
    NCT02815891
    Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
    NCT03893448
    Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
    Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Registry for Patients With Chronic Hypoparathyroidism
    NCT01922440
    Condition:   Chronic Hypoparathyroidism
    Intervention:   Drug: Combination product (Natpara) and drug or supplements [Disease and drug registry]
    Sponsor:   Shire
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC